GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » Price-to-Operating-Cash-Flow

MiNK Therapeutics (MiNK Therapeutics) Price-to-Operating-Cash-Flow : (As of Jun. 19, 2024)


View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-06-19), MiNK Therapeutics's share price is $0.8771. MiNK Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.40. Hence, MiNK Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for MiNK Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

INKT's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 24.955
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

MiNK Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $-0.07. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.40.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -16.00% per year.

During the past 5 years, MiNK Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 1.40% per year. The lowest was -16.00% per year. And the median was -7.30% per year.


MiNK Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for MiNK Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics Price-to-Operating-Cash-Flow Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
- - - - -

MiNK Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MiNK Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, MiNK Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiNK Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's Price-to-Operating-Cash-Flow falls into.



MiNK Therapeutics Price-to-Operating-Cash-Flow Calculation

MiNK Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=0.8771/-0.404
=

MiNK Therapeutics's Share Price of today is $0.8771.
MiNK Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

MiNK Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


MiNK Therapeutics (MiNK Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.
Executives
Agenus Inc 10 percent owner 3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen director 3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg director
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin officer: Treasurer 3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell director, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum director 3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni director 3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner director 3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius officer: Chief Technology Officer 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010